LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Britain Courts Anthropic Amid US Defense Department Dispute 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
OXFORD, UNITED KINGDOM, Aug. 03, 2017 -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, announces that Mr Erik Ostrowski, CFO of Summit, will present a corporate overview at the Canaccord Genuity Growth Conference on 9 August 2017 at 10:30am EDT in Boston, Massachusetts, US.
A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
-END-
For more information, please contact: Summit Therapeutics Glyn Edwards / Richard Pye (UK office) Tel: +44 (0)1235 443 951 Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455 Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson Tel: +44 (0)20 7213 0880 N+1 Singer (Broker) Aubrey Powell / Lauren Kettle Tel: +44 (0)20 7496 3000 MacDougall Biomedical Communications (US media contact) Tel: +1 781 235 3060 Karen Sharma [email protected] Consilium Strategic Communications (Financial public relations, UK) Tel: +44 (0)20 3709 5700 Mary-Jane Elliott / Sue Stuart / [email protected] Jessica Hodgson / Lindsey Neville
